These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 43870)

  • 1. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.
    Dreyfuss J; Griffith DL; Singhvi SM; Shaw JM; Ross JJ; Vukovich RA; Willard DA
    J Clin Pharmacol; 1979; 19(11-12):712-20. PubMed ID: 43870
    [No Abstract]   [Full Text] [Related]  

  • 2. Nadolol, a once daily treatment for hypertension: multi-centre clinical evaluation.
    Jackson DA
    Br J Clin Pract; 1980 Jul; 34(7):211-21. PubMed ID: 6107120
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic studies in patients with nadolol: oral and intravenous administration.
    Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA
    J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.
    Frithz G
    Curr Med Res Opin; 1978; 5(5):383-7. PubMed ID: 26519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nadolol (Corgard) - a new beta-blocker.
    Med Lett Drugs Ther; 1980 Apr; 22(8):33-4. PubMed ID: 6102734
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of betaxolol (Kerlone) as a once-daily treatment for hypertension in 4685 patients.
    Djian J
    Br J Clin Pract; 1985 May; 39(5):188-91. PubMed ID: 2866790
    [No Abstract]   [Full Text] [Related]  

  • 9. Nadolol: a new beta-adrenoceptor antagonist.
    Frishman WH
    N Engl J Med; 1981 Sep; 305(12):678-82. PubMed ID: 6115316
    [No Abstract]   [Full Text] [Related]  

  • 10. Ro 31-1118, a new cardioselective beta-adrenoceptor antagonist. Pharmacokinetics and effects on heart rate and blood pressure in mild hypertensives.
    Jamieson M; Petrie JC; Webster J; Miller A; Harris RI; Francis RJ
    Eur J Clin Pharmacol; 1985; 29(4):395-9. PubMed ID: 2868899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.
    Regårdh CG
    Acta Pharmacol Toxicol (Copenh); 1975; 37(1):1-39. PubMed ID: 237402
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of the new beta-adrenoceptor blocker SL 75212 in man after repeated oral administration [proceedings].
    Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Morselli PL; Thébault JJ; Trocherie S
    Br J Clin Pharmacol; 1979 Oct; 8(4):408P. PubMed ID: 41560
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of a new beta-adrenergic blocking agent, the 1, ter-butyl-amino-3-(1,2,3,4-tetrahydro-1,4-ethano-8-hydroxy-5-naphthoxy)-2-propanol (K 5407).
    Goldaniga G; Montesanti L; Pianezzola E; Valzelli G
    Eur J Drug Metab Pharmacokinet; 1980; 5(1):9-20. PubMed ID: 6104601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.
    Gillies HC; Rogers HJ; Francis RJ; Galloway DB; Humphreys JE
    Eur J Clin Pharmacol; 1986; 31(1):113-5. PubMed ID: 2877883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.
    Leopold G; Pabst J; Ungethüm W; Bühring KU
    J Clin Pharmacol; 1986; 26(8):616-21. PubMed ID: 2878941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of orally and topically administered beta blockers for chronic simple glaucoma.
    Williamson J; Young JD; Atta H; Muir G; Kadom H
    Br J Ophthalmol; 1985 Jan; 69(1):41-5. PubMed ID: 2856893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol.
    Mancia G; Ferrari A; Pomidossi G; Parati G; Bertinieri G; Grassi G; Gregorini L; di Rienzo M; Zanchetti A
    Am Heart J; 1984 Oct; 108(4 Pt 2):1078-83. PubMed ID: 6148866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nadolol + bendroflumethiazide in a fixed combination and in sequential administration. Experimental research on antihypertensive efficacy and tolerability].
    Del Re ML; Ricci A; Abate G
    Clin Ter; 1986 Mar; 116(5):385-90. PubMed ID: 2871962
    [No Abstract]   [Full Text] [Related]  

  • 19. Nadolol and propranolol in the treatment of hypertension: a double-blind comparison.
    El Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    J Int Med Res; 1980; 8(3):193-8. PubMed ID: 6104614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
    Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
    Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.